Here is an excerpt from MSAA's article on this latest MS treatment news:
"On February 13, 2018, Sandoz, a Novartis division, announced that the United States Food and Drug Administration (FDA) approved Glatopa® (glatiramer acetate injection) at a three-times weekly 40-mg dose. This fully-substitutable generic version of Copaxone®, a disease-modifying therapy (DMT) approved for the treatment of relapsing forms of multiple sclerosis (MS), was initially approved at a 20-mg daily dose. Both dosing options are given via self-injection and will continue to be available to individuals taking the medication.
Copaxone was initially approved in 1996 as a daily 20-mg injection. A 40-mg dose of Copaxone injected three-times weekly was approved by the FDA in 2014. In 2015, Glatopa was approved as the first generic version of Copaxone, given at the original 20-mg daily dose. This most recent approval allows people to have the option of choosing a three-times weekly dose of Glatopa in place of the daily dose, depending on their preferences. In October 2017, Mylan’s generic version of Copaxone was approved at both doses."
For more on the new dose Glatopa, you can read MSAA's full news article here:
- John, MSAA